SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-18-018256
Filing Date
2018-08-01
Accepted
2018-08-01 07:46:33
Documents
50
Period of Report
2018-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ntla-10q_20180630.htm 10-Q 1575836
2 EX-31.1 ntla-ex311_6.htm EX-31.1 17030
3 EX-31.2 ntla-ex312_7.htm EX-31.2 17040
4 EX-32.1 ntla-ex321_8.htm EX-32.1 6190
  Complete submission text file 0001564590-18-018256.txt   5441081

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT ntla-20180630.xml EX-101.INS 1290312
6 XBRL TAXONOMY EXTENSION SCHEMA ntla-20180630.xsd EX-101.SCH 34902
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ntla-20180630_cal.xml EX-101.CAL 22822
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ntla-20180630_def.xml EX-101.DEF 89355
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20180630_lab.xml EX-101.LAB 260018
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20180630_pre.xml EX-101.PRE 191599
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 18983050
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Assistant Director 1